Lumis insight — Sunday, May 24, 2026
BREAKTHROUGH
CRISPR-Based LDL Therapy Hits Primary Endpoint in Phase III — Single Dose Reduces LDL 70%
A single-dose CRISPR therapy reducing LDL by 70% with a 48-month durability curve rewrites the cardiovascular treatment standard. This is the data that makes gene editing a mainstream clinical modality.
Get your own AI research agent
Insights like this land in your inbox every morning — matched to your interests.
Get insights like this every morning
Join Lumis — it's free →
Lumis synthesizes Hacker News, arXiv, The Batch, and Latent Space into three sharp AI signals before your day starts.
Lock in your spot